Tirzepatide, Semaglutide, and Branded vs Compounded: A 2026 Comparison is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.
A friend of mine, a nurse practitioner in Memphis who runs a cash-pay obesity clinic, told me something last fall that stuck: “Half my new patients walk in with a screenshot from TikTok and say, ‘I want whatever this is.’ The other half come in with a spreadsheet comparing every GLP-1 option they can find. Both groups need the same conversation, they just need it at different speeds.” That conversation is the one I’m trying to lay out here. Not a sales pitch, not a scare piece. Just the comparison as it actually stands in 2026.
What Makes These Two Molecules Different
Let’s get the pharmacology out of the way first because it matters for the rest of the discussion.
Semaglutide (the molecule behind Ozempic and Wegovy) is a GLP-1 receptor agonist. It mimics one gut hormone. Half-life of roughly 7 days, which is why weekly dosing works.
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. It mimics two gut hormones. Similar half-life, same weekly schedule. That added GIP receptor activity is the single structural difference, and it appears to be a meaningful one.
Both slow gastric emptying through GLP-1 receptor activation in the brainstem and vagal afferents. That’s the mechanism behind the “I just don’t think about food the same way” effect patients describe. It’s also the mechanism behind the nausea.
The head-to-head numbers: the STEP-1 trial (Wilding et al., NEJM 2021) showed semaglutide 2.4 mg producing a mean 14.9% weight loss over 68 weeks. SURMOUNT-1 (Jastreboff et al., NEJM 2022) showed tirzepatide hitting 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks. SURMOUNT-5, presented in 2024, put them directly against each other and tirzepatide came out ahead on mean weight reduction over 72 weeks.
Tirzepatide wins the averages. But averages are tricky. Some people lose 25% of their body weight on semaglutide alone. Others plateau at 8% on tirzepatide 15 mg. Population data tells you the likelihood, not your outcome.
My honest opinion: if cost and access were identical, tirzepatide would probably be the default first choice for most obesity patients. But cost and access are very much not identical, which is why the rest of this article exists.
Branded vs. Compounded: What You’re Actually Choosing Between
The active ingredient doesn’t change when you move from branded to compounded. Tirzepatide is tirzepatide. What changes is everything surrounding the molecule: manufacturing oversight, packaging, pricing, and regulatory status.
Branded products (Zepbound, Mounjaro) are FDA-approved finished drugs made by Eli Lilly under current Good Manufacturing Practice standards. They come with established labels, post-marketing surveillance, and the full regulatory apparatus. Insurance may cover them, depending on your plan, your BMI, and whether Mercury is in retrograde. (I’m only half joking. Formulary decisions can feel that arbitrary.)
Compounded preparations are produced by 503A pharmacies (patient-specific prescriptions) or 503B outsourcing facilities (cGMP-inspected, can produce office stock). They are not FDA-evaluated for safety, efficacy, or quality in the way branded products are. Oversight comes from state pharmacy boards, federal 503A/503B requirements, and the prescribing clinician’s judgment.
One practical advantage compounded preparations offer: intermediate dosing. Branded autoinjectors come in fixed increments (2.5, 5, 7.5, 10, 12.5, 15 mg). Compounded formulations can be prepared at 6.25 or 8.75 mg, which is useful when a patient tolerates 5 mg fine but gets hammered by 7.5. That flexibility matters more than it sounds like it should.
Patients considering compounded options should look at three things: pharmacy credentialing (state licensure, accreditation where applicable), clinical oversight (a real clinician evaluation, not just a checkbox form), and pricing transparency. If you can’t get a straight answer on what a three-month supply costs, that’s a red flag.
A more detailed treatment of all of this is available in this drug comparison (sema vs tirz vs brand) guide, which covers dosing protocols, side effect management, and the regulatory framework more thoroughly than I can here. Worth reading alongside anything with a marketing budget behind it.
Titration: The Part Most People Underestimate
The boring truth about GLP-1 therapy is that the first month is largely about your gut learning to tolerate the drug, not about weight loss. Here’s what standard tirzepatide titration looks like:
| Phase | Typical dose | Duration | Notes | |—|—|—|—| | Initiation | 2.5 mg weekly | Weeks 1 to 4 | Tolerance phase. Minimal weight loss expected. | | Step 1 | 5 mg weekly | Weeks 5 to 8 | First meaningful appetite reduction for most patients. | | Step 2 | 7.5 mg weekly | Weeks 9 to 12 | Some protocols hold here if response is adequate. | | Step 3 | 10 mg weekly | Weeks 13 to 16 | Common long-term maintenance tier. | | Step 4 | 12.5 mg weekly | Weeks 17 to 20 | For patients with attenuating response. | | Step 5 | 15 mg weekly | Week 21 onward | Maximum labeled dose. Not everyone needs this. |
Not every patient should or will reach 15 mg. Many stabilize somewhere between 5 and 10 mg once they hit their goal weight, with the dose chosen to balance continued benefit against side effects and cost. Dose escalation for its own sake is poor medicine.
Side Effects: Predictable, Usually Manageable, Occasionally Not
GI symptoms dominate. This is not a surprise when you’re working with a drug whose mechanism literally slows your digestive tract.
| Symptom | Reported frequency | Typical timing | Management | |—|—|—|—| | Nausea | 30 to 45% | First 4 to 8 weeks, worse at dose increases | Smaller meals, lower fat, slow water sipping, antiemetic if persistent | | Diarrhea | 15 to 23% | Variable | Hydration, electrolyte review, BRAT-style meals briefly | | Constipation | 10 to 17% | Often after GI slowing kicks in | Fiber 25 to 35 g daily, hydration, magnesium if cleared by clinician | | Vomiting | 8 to 13% | First weeks and escalations | Hold dose, contact prescriber if persistent | | Reflux | 7 to 12% (often underreported) | Throughout therapy | No eating within 3 hours of bedtime, head-of-bed elevation | | Fatigue | Variable | First weeks | Usually self-resolves. Check ferritin, B12, thyroid if it lingers. |
Most of this concentrates in the first few weeks and around dose increases. Severity typically peaks shortly after a step-up, then fades over 2 to 3 weeks at a stable dose.
The serious stuff: pancreatitis, gallbladder disease, severe hypoglycemia (especially combined with insulin or sulfonylureas), kidney injury from severe dehydration, and a boxed warning for medullary thyroid carcinoma based on rodent studies. These are rare but real, which is why baseline labs matter.
Reasonable baseline panel before starting: comprehensive metabolic panel (CMP), HbA1c and fasting glucose, lipid panel, TSH, lipase if there’s any personal history of pancreatitis, and CBC. Repeat at 12 to 16 weeks, then roughly every 6 months once stable. Severe abdominal pain radiating to the back warrants immediate clinician contact, not a “let me wait until my next appointment” approach.
See also: Techsuse
How Patients Actually Make This Decision
In practice, the choice comes down to a handful of factors that overlap in messy, individual ways:
Diabetes status. Both molecules have diabetes indications. Mounjaro and Ozempic are FDA-labeled for type 2 diabetes; Zepbound and Wegovy for chronic weight management. If you have type 2 diabetes, that shapes both the clinical choice and the insurance conversation.
BMI and comorbidities. Insurance coverage for branded weight management products typically requires BMI of 30 or higher (or 27 with comorbidities like hypertension, type 2 diabetes, or dyslipidemia). No documentation, no coverage. Simple as that.
Cost tolerance. Cash-pay patients without coverage gravitate toward compounded options. Patients with solid formulary coverage typically stick with branded. The price gap can be enormous.
Prior experience. Someone who tolerated semaglutide well but plateaued might consider tirzepatide for the additional weight loss potential. Someone with prior GLP-1 intolerance needs a careful conversation before switching molecules rather than just swapping prescriptions.
Adherence reality. The right drug is the one you’ll actually take consistently while doing the supporting work (nutrition, movement, sleep). A theoretically superior molecule sitting unused in your fridge produces zero outcomes. This sounds obvious. It is obvious. And yet.
What to Discuss with Your Prescriber
Before starting: full medical history review, medication interaction check, baseline labs, and a frank conversation about realistic expectations. Not “you’ll lose 20% of your body weight” but “here’s the range of outcomes, here’s the timeline, here’s what we’ll monitor.”
During titration: how you’re tolerating the current dose, whether side effects justify slowing escalation, hydration and nutrition adequacy, and any symptoms that need attention now rather than later.
At maintenance: dose stabilization, lab monitoring schedule, long-term planning, and pregnancy considerations if applicable.
Any severe or persistent symptom warrants a call to your clinician. Don’t wait for the next scheduled visit.
Frequently Asked Questions
Is tirzepatide more effective than semaglutide?
On average, yes. SURMOUNT-5 (2024) showed tirzepatide achieving greater mean weight reduction than semaglutide over 72 weeks. But individual responses vary considerably, and the best choice depends on tolerability, cost, access, and patient-specific clinical factors.
What are the practical differences between the molecules?
Semaglutide activates GLP-1 receptors. Tirzepatide activates both GIP and GLP-1 receptors. That dual action appears to contribute to the greater mean weight loss and some differences in metabolic effects seen in clinical data.
Can I switch between them?
Yes, under clinician guidance. The standard approach is to start the new molecule at its lowest dose rather than trying to dose-match, then retitrate based on tolerance.
Which has more side effects?
Both share GLP-1-driven GI side effects: nausea, constipation, diarrhea. Reported rates in trial data are broadly similar. Individual variation is significant.
Is branded better than compounded?
Branded products carry FDA manufacturing oversight, established labeling, and post-marketing surveillance. Compounded preparations are not FDA-approved. It’s less a question of “better” as a category and more about which option fits your clinical context, cost situation, and access.
How do I decide which to start?
Talk to a clinician who can review your full history. The decision usually weighs diabetes status, BMI, side effect history with any prior agents, cost, and the practical logistics of getting and staying on treatment.
Important regulatory note. Compounded tirzepatide is not FDA-approved. It is prepared by licensed 503A or 503B pharmacies for individual patients based on a prescriber’s clinical judgment. Compounded preparations are not evaluated by the FDA for safety, efficacy, or quality the way branded products are. Research suggests outcomes vary between patients, and any decision to begin, modify, or discontinue therapy should occur in coordination with a licensed clinician who can review your medical history, current medications, and laboratory values.
